TrovaGene, Inc. (TROV) to Post FY2017 Earnings of ($1.04) Per Share, Cantor Fitzgerald Forecasts

TrovaGene, Inc. (NASDAQ:TROV) – Equities researchers at Cantor Fitzgerald issued their FY2017 EPS estimates for TrovaGene in a research note issued to investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein anticipates that the medical research company will post earnings of ($1.04) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. Cantor Fitzgerald also issued estimates for TrovaGene’s FY2018 earnings at ($0.80) EPS.

Separately, Maxim Group reaffirmed a “buy” rating and set a $4.00 price target on shares of TrovaGene in a research report on Friday, May 5th.

ILLEGAL ACTIVITY WARNING: “TrovaGene, Inc. (TROV) to Post FY2017 Earnings of ($1.04) Per Share, Cantor Fitzgerald Forecasts” was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.com-unik.info/2017/08/12/trovagene-inc-trov-to-post-fy2017-earnings-of-1-04-per-share-cantor-fitzgerald-forecasts.html.

Shares of TrovaGene (NASDAQ TROV) opened at 0.85 on Thursday. The firm has a 50-day moving average price of $1.04 and a 200-day moving average price of $1.22. TrovaGene has a 52 week low of $0.61 and a 52 week high of $5.98. The firm’s market cap is $31.68 million.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. LMR Partners LLP purchased a new position in shares of TrovaGene during the second quarter valued at about $151,000. Two Sigma Securities LLC raised its position in shares of TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock valued at $139,000 after buying an additional 87,264 shares in the last quarter. Finally, KCG Holdings Inc. raised its position in shares of TrovaGene by 560.1% in the first quarter. KCG Holdings Inc. now owns 210,301 shares of the medical research company’s stock valued at $242,000 after buying an additional 178,440 shares in the last quarter. 15.19% of the stock is owned by hedge funds and other institutional investors.

TrovaGene Company Profile

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

What are top analysts saying about TrovaGene Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TrovaGene Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit